search

Active clinical trials for "Motor Neuron Disease"

Results 421-430 of 760

Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)...

Amyotrophic Lateral Sclerosis (ALS)

ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function. While there are drugs to help relieve symptoms of ALS, there is no cure for ALS. Rasagiline is a drug with possible neuroprotective characteristics. Neuroprotective means that the nervous system may be protected against weakening. It is known that rasagiline has possible neuroprotective characteristics and it is approved for use for patients with another disorder, the effectiveness of rasagiline for patients with ALS has not been tested.

Completed22 enrollment criteria

Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram...

Amyotrophic Lateral Sclerosis

To evaluate whether dexpramipexole prolongs the QTc interval when orally administered to healthy volunteers.

Completed10 enrollment criteria

Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF),...

Amyotrophic Lateral Sclerosis

The study will evaluate the safety, tolerability and therapeutic effects (preliminary efficacy) of injection of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), as a possible treatment for patients with Amyotrophic Lateral Sclerosis (ALS) at the early and progressive disease stages.

Completed18 enrollment criteria

Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)...

Amyotrophic Lateral Sclerosis

The investigators want to test feasibility of a structured program of telesurveillance and home cough assistance for ALS patients.

Completed2 enrollment criteria

Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic...

Amyotrophic Lateral Sclerosis

The purpose of this study will be to demonstrate the safety, tolerability, and efficacy of arimoclomol in subjects with SOD1 positive familial Amyotrophic Lateral Sclerosis (ALS). This type of ALS is HEREDITARY (runs in families), and at least one other person in the family must have had ALS. Study hypotheses: Arimoclomol, taken at a dose of 200 mg three times daily will improve survival as defined by time to death, tracheostomy or permanent assisted ventilation. In addition, it will be safe and well tolerated in subjects with SOD1 positive familial ALS. Funding Source - FDA-OOPD

Completed28 enrollment criteria

Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy

Motor Neuron Disease

Background: -Spinal and bulbar muscular atrophy (SBMA) is an inherited disorder that affects men. People with SBMA often have weakness throughout the body, including the muscles they use for swallowing, breathing, and speaking. We do not know if exercise helps or harms people with SBMA. Objective: -To see if a 12-week program of either functional exercise or stretching exercises will improve strength, function, or quality of life in people with SBMA Eligibility: Participants will be men 18 years of age or older who have genetic confirmation of SBMA. They must be able to walk at least 50 feet with or without an assistive device such as a cane or a walker and stand for 10 minutes without using an assistive device. They must have access to a computer with an Internet connection. Design: At the first visit to NIH (2 days), participants will have a medical history taken and undergo a physical exam. They will also have blood tests and an EKG, and complete questionnaires about mood, health, and exercise. Tests of muscle strength, balance, and endurance will also be done. Participants who qualify for the study will receive instruction about either strengthening or stretching exercises. They will do these exercises at home one to three times a week for 12 weeks. They will wear a small activity monitor while they exercise and record their exercise in a diary. At the end of 12 weeks, participants will return to the NIH for 2 days. They will undergo the same tests as they had on the first visit. Participants will receive follow-up phone calls and e-mails during the study and for 4 weeks after the last visit....

Completed15 enrollment criteria

Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral...

Amyotrophic Lateral SclerosisALS

The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow-derived stem cells("HYNR-CS inj"), through intrathecal delivery for the treatment in patients with ALS. This study consists of 2 steps. First step is a safety study of the intrathecal(IT) injection of "HYNR-CS inj" in 8 patients with ALS. In this phase 1 study, AE, laboratory test, physical examination, vital signs, Electrocardiogram, and Chest X-Ray examination were evaluated in terms of safety. Second step is to compare the efficacy and safety between test group and control group of total 64 patients with ALS.

Completed29 enrollment criteria

The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral...

Amyotrophic Lateral Sclerosis

The purpose of the study is to investigate the effects of memantine in ALS patients using functional outcome measures.

Completed11 enrollment criteria

Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS

Amyotrophic Lateral Sclerosis

Muscular cramps are a common and uncomfortable symptom of amyotrophic lateral sclerosis (ALS). This clinical trial will compare the response of high dose vitamin E supplementation to placebo for treatment of muscular cramps in patients with ALS. We hypothesize that vitamin E will be more effective than placebo in treating cramps.

Completed10 enrollment criteria

Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)

Amyotrophic Lateral Sclerosis

The purpose of this trial is to study the effect of Memantine (uncompetitive, moderate affinity, NMDA receptor antagonist that binds to the NMDA receptor channel, and regulates the calcium influx into the neurons), a drug used to treat Alzheimer´s disease, on the progression of Amyotrophic Lateral Sclerosis (ALS). Memantine is added to riluzole (the single drug approved to treat ALS).

Completed10 enrollment criteria
1...424344...76

Need Help? Contact our team!


We'll reach out to this number within 24 hrs